DPP4 and COVID-19: Consistently, IPTW-adjusted logistic regression confirmed a significant association between DPP-4 inhibitor use and reduced COVID-19-related mortality (OR: 0.30; 95% CI: 0.27–0.34; p < 0.001), reinforcing the robustness of our primary findings.